Aripiprazole augmentation in managing comorbid obsessive–compulsive disorder and bipolar disorder: a case with suicidal attempts
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Comorbid obsessive-compulsive disorder (OCD) and bipolar disorder (BD) have long been an intractable problem in clinical practice. The increased risk of manic/hypomanic switch hinders the use of antidepressants for managing coexisting OCD symptoms in BD patients. We herein present a case of a patient with BD-OCD comorbidity, who was successfully treated with mood stabilizers and aripiprazole augmentation. The young female patient reported recurrent depressive episodes and aggravating compulsive behaviors before hospitalization. Of note, the patient repetitively attempted suicide and reported dangerous driving because of intolerable mental sufferings. The preexisting depressive episode and OCD symptoms prompted the use of paroxetine, which consequently triggered the manic switching. Her diagnosis was revised into bipolar I disorder. Minimal response with mood stabilizers prompted the addition of aripiprazole (a daily dose of 10 mg), which helped to achieve significant remission in emotional and obsessive-compulsive symptoms. This case highlights the appealing efficacy of a small dose of aripiprazole augmentation for treating BD-OCD comorbidity. Well-designed clinical trials are warranted to verify the current findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Two published case reports described successfully employing aripiprazole once monthly753 and orally754 for patients with intractable bipolar and OCD symptoms.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dold, M., Aigner, M., Lanzenberger, R., & Kasper, S. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000740 · Cited by 211
Aripiprazole: A Novel Atypical Antipsychotic Drug With a Uniquely Robust Pharmacology
Davies, M. A., Sheffler, D. J., & Roth, B. L. (2004) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2004.tb00030.x · Cited by 156 · cited 1×
“9 Aripiprazole monotherapy, or as an adjuvant to mood stabilizers, is efficacious in managing acute mania and stabilization phases of BD, but not bipolar depression.”
BackgroundPerugi, G., Toni, C., Frare, F., Travierso, M. C., Hantouche, E. G., & Akiskal, H. S. (2002) · PubMed · Cited by 142
Dold, M., Aigner, M., Lanzenberger, R., & Kasper, S. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv047 · Cited by 134
Amerio, A., Odone, A., Liapis, C. C., & Ghaemi, S. N. (2014) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12250 · Cited by 109 · cited 1×
“6 In other words, the OCD symptoms in these individuals were part of BD rather than a separate disease.”
BackgroundSayyah, M., Sayyah, M., Boostani, H., Ghaffari, S. M., & Hoseini, A. (2012) · Depression and Anxiety · doi:10.1002/da.21996 · Cited by 105 · cited 1×
“11,12 However, long-term use of aripiprazole is associated with increased risk of extrapyramidal syndromes (EPSs).”
BackgroundRingbäck Weitoft, G., Berglund, M., Lindström, E. A., Nilsson, M., Salmi, P., & Rosén, M. (2014) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3567 · Cited by 77 · cited 1×
“Moreover, aripiprazole users had reported significantly lower risk of all-cause mortality among various antipsychotics.(19) Given the recurrent onset of suicidal attempts in our patient, special attention should be paid to the suicidal profiles of antipsychotic augmentation in BD–OCD patients.”
BackgroundTreatment of comorbid bipolar disorder and obsessive–compulsive disorder: A systematic review
Amerio, A., Odone, A., Marchesi, C., & Ghaemi, S. N. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.05.026 · Cited by 71 · cited 1×
“5 However, due to the lack of well-designed clinical trials, case reports of successful treatment in patients with comorbid BD–OCD are of important reference value for clinical practice.”
BackgroundClinical management of obsessive‐compulsive‐bipolar comorbidity: a case series
Raja, M., & Azzoni, A. (2004) · Bipolar Disorders · doi:10.1111/j.1399-5618.2004.00109.x · Cited by 39
Uğuz, F. (2010) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2010.07.004 · Cited by 33 · cited 2×
“13 Several antipsychotics, including risperidone, 14 olanzapine, 15 quetiapine, 16 and aripiprazole, 7,8 were suggested due to the benefits in relieving the OCD symptoms in BD patients.”
BackgroundMeduri, M., Gregoraci, G., Baglivo, V., Balestrieri, M., Isola, M., & Brambilla, P. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.11.033 · Cited by 26 · cited 2×
“However, long-term use of aripiprazole is associated with increased risk of extrapyramidal syndromes (EPSs).(10) Therefore, defining the minimum effective dose of aripiprazole is essential for preventing EPSs.”
BackgroundEpidemiologic study of aripiprazole use and the incidence of suicide events
Ulcickas Yood, M., DeLorenze, G., Quesenberry, C. P., Tsai, A., Phillips, S., Willey, V. J., Niemcryk, S. J., Wells, K., Skovron, M. L., Cziraky, M. J., et al. (2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2047 · Cited by 22 · cited 1×
“However, epidemiological data in large sample revealed that consuming aripiprazole was not associated with more suicide events compared to other atypical antipsychotics.(18) Moreover, aripiprazole users had reported significantly lower risk of all-cause mortality among various antipsychotics.”
ResultComorbid obsessive–compulsive disorder with bipolar disorder: A distinct form?
Özdemiroğlu, F., Sevinçok, L., Sen, G., Mersin, S., Kocabaş, O., Karakus, K., & Vahapoglu, F. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.11.002 · Cited by 21
Comorbid bipolar disorder and obsessive-compulsive disorder: Which came first?
Tonna, M., Amerio, A., Odone, A., Stubbs, B., & Ghaemi, S. N. (2016) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415621395 · Cited by 21 · cited 1×
“Symptoms of OCD may occur before, during, or after the first mood episode and, in most cases, fluctuate with mood swings.(2) In this regard, the majority of BD–OCD comorbidities are considered to be a subtype of BD, rather than two separate diseases.”
BackgroundQuetiapine as adjunctive treatment of a case of rapid‐cycling bipolar disorder with comorbidity
Stratta, P., de Cataldo, S., Mancini, G., Gianfelice, D., Rinaldi, O., & Rossi, A. (2003) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.523 · Cited by 11 · cited 1×
“13 Several antipsychotics, including risperidone, 14 olanzapine, 15 quetiapine, 16 and aripiprazole, 7,8 were suggested due to the benefits in relieving the OCD symptoms in BD patients.”
BackgroundPatra, S. (2016) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416656262 · Cited by 9 · cited 2×
“13 Several antipsychotics, including risperidone, 14 olanzapine, 15 quetiapine, 16 and aripiprazole, 7,8 were suggested due to the benefits in relieving the OCD symptoms in BD patients.”
BackgroundEffective Use of Olanzapine for Obsessive—Compulsive Symptoms in a Patient with Bipolar Disorder
Petrikis, P., Andreou, C., Bozikas, V. P., & Karavatos, A. (2004) · The Canadian Journal of Psychiatry · doi:10.1177/070674370404900812 · Cited by 8
New-Onset Psychosis and Emergence of Suicidal Ideation With Aripiprazole
Selvaraj, V., Ramaswamy, S., Sharma, A., & Wilson, D. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10020238 · Cited by 7 · cited 1×
“17 However, epidemiological data in large sample revealed that consuming aripiprazole was not associated with more suicide events compared to other atypical antipsychotics.”
ResultComorbid Bipolar Disorder and Obsessive-Compulsive Disorder: An Old Debate Renewed
Amerio, A., Tonna, M., Odone, A., & Ghaemi, S. N. (2016) · Psychiatry Investigation · doi:10.4306/pi.2016.13.3.370 · Cited by 5 · cited 1×
“In this regard, the majority of BD–OCD comorbidities are considered to be a subtype of BD, rather than two separate diseases.(3) To date, no standard pharmacotherapy for cooccurring BD–OCD has been established.”
Background
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Kim, D., Ryba, N., Kalabalik, J., & Westrich, L. (2018) · Drugs in R&D · doi:10.1007/s40268-018-0246-8 · Cited by 38
“In the three published cases, aripiprazole was added to a high-dose mood-stabilizing medication, such as lithium, and the patients experienced clinical improvement [47, 55, 60].”
BackgroundUpdates in treating comorbid bipolar disorder and obsessive-compulsive disorder: A systematic review
Amerio, A., Maina, G., & Ghaemi, S. N. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.06.015 · Cited by 28
Sahraian, A., Ehsaei, Z., & Mowla, A. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.03.014 · Cited by 23
“In review of the literature, a few case reports of successful treatment of OCD and BD comorbidity with aripiprazole were found (Uguz, 2010; Lai et al., 2016).”
BackgroundKhorshidian, F., Hamidia, A., Kheirkhah, F., Moghadamnia, A. A., Bijani, A., Mirtabar, S. M., & Koutanaei, S. J. (2023) · Health Science Reports · doi:10.1002/hsr2.1531 · Cited by 7
Metadata
- Authors
- Lai, J., Lu, Q., Zhang, P., Xu, T., Xu, Y., & Hu, S.
- Affiliations
- First Affiliated Hospital Zhejiang University (CN)
- Corresponding author
- Xu, Yi
- Hu, Shaohua
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2016-12
- Volume
- Volume 13
- Pages
- 87-90
- ISSN
- 1176-6328 (ISSN-L)
- 1178-2021
- PMC
- PMC5207469
- OpenAlex
- W2565516624
- Cited by
- 9
- References
- 19
- Citations by year
- 2023: 1 · 2022: 1 · 2019: 2 · 2018: 4 · 2017: 1
- FWCI
- 2.07
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Neuropsychiatric Disease and Treatment (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- aripiprazole, augmentation therapy, obsessive-compulsive disorder, bipolar disorder, comorbidities, bipolar I disorder, suicide attempts, paroxetine, mood stabilizers, depressive episodes, compulsive behavior, bipolar depression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.